Literature DB >> 12846770

The role of hyperparathyroidism, erythropoietin therapy, and CMV infection in the failure of arteriovenous fistula in hemodialysis.

Giuseppe Grandaliano1, Annalisa Teutonico, Arcangelo Allegretti, Riccardo Losappio, Andrea Mancini, Loreto Gesualdo, Francesco Paolo Schena, Giovanni Pertosa.   

Abstract

BACKGROUND: Vascular access failure is the main cause of morbidity in hemodialysis. Venous stenosis and subsequent thrombosis, as the result of intimal hyperplasia, is the major cause of vascular access failure. Intimal hyperplasia of the arteriovenous fistula (AVF) closely resembles the main histopathologic feature of atherosclerosis. In addition to the classic atherogenic risk factors, recently, cytomegalovirus (CMV) infection and parathyroid hormone (PTH) have been suggested as a potential cause of vascular disease.
METHODS: In the present study, we evaluated the relationship between AVF dysfunction and mean plasma PTH, cholesterolemia, high titer anti-CMV immunoglobulin G (IgG) (>250 U/mL), hematocrit, and mean erythropoietin (EPO) dose in 36 cases and 51 controls matched for age, time on dialysis, and type of AVF.
RESULTS: A higher percentage of patients with AVF failure had a smoking habit and presented high anti-CMV IgG titer. Patients with AVF failure had significantly higher mean plasma PTH, whereas the groups did not differ for mean cholesterolemia and hematocrit. Mean EPO dose was slightly, but significantly, higher in the AVF failure group. Multiple logistic regression revealed that smoking, EPO dose, elevated mean plasma PTH and high titer anti-CMV antibodies, significantly increased the risk of AVF dysfunction.
CONCLUSION: Our data suggest that hyperparathyroidism, smoking habits, CMV infection and EPO, independently of the hematocrit achieved, represent independent risk factors for hemodialysis access thrombosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12846770     DOI: 10.1046/j.1523-1755.2003.00120.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  9 in total

1.  Comparison of classical and non-classical cardiovascular risk factors influencing the patency of native arteriovenous fistulas after percutaneous transluminal angioplasty therapy among haemodialysis patients.

Authors:  Jiung-Hsiun Liu; Po-Wen Lin; Yao-Lung Liu; Hsin-Hung Lin; Chiu-Ching Huang
Journal:  Postgrad Med J       Date:  2007-08       Impact factor: 2.401

2.  Significant correlation between ankle-brachial index and vascular access failure in hemodialysis patients.

Authors:  Szu-Chia Chen; Jer-Ming Chang; Shang-Jyh Hwang; Jer-Chia Tsai; Chuan-Sheng Wang; Hsiu-Chin Mai; Feng-Hsien Lin; Ho-Ming Su; Hung-Chun Chen
Journal:  Clin J Am Soc Nephrol       Date:  2009-01       Impact factor: 8.237

3.  Aortic Arch Calcification Predicts Patency Loss of Arteriovenous Fistula in End-Stage Renal Disease Patients.

Authors:  Yit-Sheung Yap; Kai-Ting Ting; Wen-Che Chi; Cheng-Hao Lin; Yi-Chun Liu; Wan-Long Chuang
Journal:  Sci Rep       Date:  2016-04-22       Impact factor: 4.379

4.  IL-23 plasma level is strongly associated with CMV status and reactivation of CMV in renal transplant recipients.

Authors:  Mahmoud Sadeghi; Imad Lahdou; Gerhard Opelz; Arianeb Mehrabi; Martin Zeier; Paul Schnitzler; Volker Daniel
Journal:  BMC Immunol       Date:  2016-10-03       Impact factor: 3.615

5.  Administration of a High-Dose Erythropoietin-Stimulating Agent in Hemodialysis Patients is Associated with Late Arteriovenous Fistula Failure.

Authors:  Hye Yun Jeong; Eun Jung Ko; Sang Hoon Kim; Mi Jung Lee; Hye Jeong Cho; Dong Ho Yang; So Young Lee
Journal:  Yonsei Med J       Date:  2017-07       Impact factor: 2.759

6.  A high red blood cell distribution width predicts failure of arteriovenous fistula.

Authors:  Krzysztof Bojakowski; Mensur Dzabic; Ewa Kurzejamska; Grzegorz Styczynski; Piotr Andziak; Zbigniew Gaciong; Cecilia Söderberg-Nauclér; Piotr Religa
Journal:  PLoS One       Date:  2012-05-04       Impact factor: 3.240

7.  Link between Peripheral Artery Disease and Heart Rate Variability in Hemodialysis Patients.

Authors:  Szu-Chia Chen; Chien-Fu Chen; Jiun-Chi Huang; Mei-Yueh Lee; Jui-Hsin Chen; Jer-Ming Chang; Shang-Jyh Hwang; Hung-Chun Chen
Journal:  PLoS One       Date:  2015-08-03       Impact factor: 3.240

8.  rHuEPO hyporesponsiveness and related high dosages are associated with hyperviscosity in maintenance hemodialysis patients.

Authors:  Mehtap Erkmen Uyar; Selami Kocak Toprak; Hatice Saglam; Emre Tutal; Meltem Bay; Osman Ilhan; Zeynep Bal; Siren Sezer
Journal:  ScientificWorldJournal       Date:  2013-09-30

9.  Predictive parameters of arteriovenous fistula maturation in patients with end-stage renal disease.

Authors:  Muhammad A Siddiqui; Suhel Ashraff; Derek Santos; Robert Rush; Thomas Carline; Zahid Raza
Journal:  Kidney Res Clin Pract       Date:  2018-09-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.